NOVEL GENES FOR THE DIAGNOSIS/PROGNOSIS OF BREAST CANCER

用于乳腺癌诊断/预后的新基因

• 批准号: 6376543
• 负责人: Raymond Houghton
• 金额: $ 38.21万
• 依托单位: CORIXA CORPORATION
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 2003-07-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6376543
• 关键词: Brazil; RNase protection assay; breast neoplasm /cancer diagnosis; breast neoplasms; diagnosis design /evaluation; differential display technique; female; gene expression; genetic library; genetic mapping; genetic markers; human genetic material tag; human tissue; molecular oncology; neoplasm /cancer genetics; polymerase chain reaction; prognosis; tissue /cell culture

This proposal discusses the evaluation and development Real time PCR assays using novel breast cancer markers for the diagnosis and prognosis of human breast cancer. Breast cancer is second only to lung cancer in deaths among women in the U.S. Good prognosis depends on the early detection of the disease. However, the sensitivity and the specificity of the current available diagnostic markers is not sufficient. Using improved state of the art technology, differential display PCR and cDNA library and PCR subtraction methods, we have identified 5 novel breast cancer markers and established their tissue specificity and potential presence in micrometastases using Real time PCR. These novel genes will be further evaluated alone and/or in combination to determine the optimal combination of genes for use in Real time PCR assays to detect micrometastases and provide improved diagnosis/prognosis of breast cancer. Real time PCR with these genes on different stage tumors and micrometastases has already been achieved at Corixa and will be expanded and standardized assays developed. This in combination with collaborations with key investigators in the area of breast cancer and access to an extensive blood and tissue bank should enable the goals and objectives of this proposal to be achieved. PROPOSED COMMERCIAL APPLICATION: The proposed studies will lead to commercialization of a high throughput RT-PCR assay for diagnosis and /or prognosis of breast cancer. Such tests would be marketed both in the U.S. and worldwide. The estimated world wide market for such a tests is $200-300 million/year.

该提案讨论了使用新型乳腺癌标记物来诊断和预后的评估和开发实时PCR分析。乳腺癌仅次于美国女性死亡中的肺癌，良好的预后取决于疾病的早期发现。但是，当前可用诊断标记的灵敏度和特异性不够。使用改进的最先进的技术，差异显示PCR和cDNA文库以及PCR减法方法，我们已经确定了5种新型的乳腺癌标记物，并使用实时PCR确定了其在微转移酶中的组织特异性和潜在的存在。这些新型基因将单独评估和/或组合，以确定基因在实时PCR分析中使用以检测微转移酶的最佳组合，并提供了改进的乳腺癌诊断/预后。在不同阶段肿瘤上使用这些基因的实时PCR已经在Corixa中实现了，并将扩大并制定标准化测定。这与与乳腺癌领域的主要研究人员的合作结合在一起，并获得了广泛的血液和组织库，应实现该提案的目标和目标。拟议的商业应用：拟议的研究将导致高吞吐量RT-PCR测定法进行诊断和 /或乳腺癌预后的商业化。此类测试将在美国和全球范围内进行销售。此类测试的估计全球市场为每年2亿美元。